Cardiff Oncology reported positive Phase II signals for onvansertib in RAS‑mutated metastatic colorectal cancer while simultaneously announcing the resignations of CEO Mark Erlander and CFO James Levine. The market reacted violently: investors drove the stock down roughly 45% over two trading days and slashed the company’s market capitalization by about 46%. The board installed interim CEO Mani Mohindru and promoted long‑time finance executive Brigitte Lindsay to chief accounting officer to maintain continuity. Analysts suggested the board sought late‑stage development experience to shepherd potential Phase III plans, but investors interpreted the timing as destabilizing. Cardiff faces the immediate task of stabilizing leadership, clarifying its clinical development timeline and communicating a capital-plan to underwriters and shareholders to support potential late‑stage studies.